IMMUNABS
ImmunAbs Inc. (www.immunabs.com ) announced that it has received US FDA approval for a Phase 1 clinical trial and that it is now ready to initiate a phase 1 clinical trial in the United States.
ImmunAbs is developing IM-101, a monoclonal antibody targeting complements that play essential roles in the immune system but, when out of regulation, cause various autoimmune diseases, including but not limited to paroxysmal nocturnal hemoglobinuria (PNH). The complement inhibitors drug market showed its growth potential by achieving an average annual growth rate of 20.7% and a market size of USD $ 5.1 billion in 2020 and is expected to grow to USD $19 billion by 2027.
Paroxysmal nocturnal hemoglobinuria is one example of complement-mediated autoimmune diseases where the membrane proteins protecting the red blood cells from complement activation are lost due to mutations, which results in red blood cells being destructed by the complements. Due to insufficient inhibition of complements shown by currently approved complement inhibitors, SolirisⓇ and UltomirisⓇ , patients who receive these drugs still suffer from the residual symptoms of PNH, which include anaemia, fatigue, and decreased productivity at work.
ImmunAbs’ new complement therapeutic IM-101 targets the safest and most potent component of the complement system, complement C5. IM-101 has been shown to completely inhibit complement activation, and thus is expected to alleviate the symptoms that persist with the standard of care. ImmunAbs will initiate a phase 2a clinical trial in the United States in 2024.
“This is a historical milestone for ImmunAbs.” said Dr. DongJo Kim, the company’s CEO. “We are delighted to see IM-101’s efficacy in humans which has been proven in our ex vivo study. We hope that our IM-101 will reach patients who may suffer from symptoms that persist due to insufficient complement inhibition by the current treatments.”
About ImmunAbs Inc.
ImmunAbs Inc. was established in 2017 by experts of global standard antibody therapeutics development. The vision is "Hope for Patients, Dreams for All." Currently, ImmunAbs has several antibody therapeutics in global standard development for autoimmune diseases, diabetic retinopathy, and metabolic syndrome. ImmunAbs successfully raised KRW 18.1 billion from Seed to series A funding in 2021 and got a non-clinical study national grant for developing IM-101 from Korea Drug Development Fund in November last year.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220803005380/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting styrker sine kompetencer med BMA27.11.2025 22:48:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for bæredygtighed og virksomhedsforandring gennem en samarbejdsaftale med BMA, der er et sydafrikansk firma, som arbejder for at styrke konkurrenceevnen i fremstillingsindustrien og fremme inkluderende industriel vækst. BMA, der blev etableret for mere end to årtier siden, arbejder på tværs af produktionsværdikæder – fra producenter til deres kunder – sammen med myndigheder og udviklingsagenturer for at fremme bæredygtig industriel konkurrenceevne. Gennem sine sektorfokuserede industrielle klynger leverer firmaet integrerede tjenester inden for industriel politik og strategisk udvikling, værdikædestrategi, produktionskonkurrenceevne og lean-rådgivning, reduktion af CO2-udledning samt udvikling af små og mellemstore virksomheder og samler interessenter omkring fælles prioriteter og skalerbare, langsigtede løsninger. "Bæredygtig produktion handler om mere end effektivitet. Det drejer sig om at skabe økosystemer, der er regenerative, resi
Stronghold’s SHx Token Lists on Uphold27.11.2025 16:00:00 CET | Press release
Multi-Chain Expansion Accelerates With New Listing on a Trusted Platform Supporting Both Stellar and Ethereum Stronghold announced that its SHx token is now available for retail users to trade on Uphold, the global multi-asset digital money platform known for its transparency, regulatory alignment, and seamless support for assets across both the Stellar and Ethereum networks. The listing marks a major milestone for SHx, expanding access for users and businesses who rely on Stronghold’s token for payments, settlements, and governance participation. "Uphold is one of the only platforms that provides seamless support for both Stellar and Ethereum-based tokens, making it a perfect fit for SHx as we grow our multi-chain ecosystem. This listing was championed by our community, and we’re thrilled to deliver on a request that so many SHx holders have been asking for." — Tammy Camp, CEO & Co-Founder, Stronghold SHx is Stronghold’s native utility token, powering interoperable payments, DeFi-base
Wipro to Power Odido’s Digital Future Through AI-enabled End-to-End IT Modernization27.11.2025 14:22:00 CET | Press release
The multi-year engagement marks a significant shift in Odido’s IT strategywith Wipro bringing deep domain expertise, AI-powered delivery, and a design-led approach to drive innovation Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading AI-powered technology services and consulting company, today announced a multi-year engagement with Odido Netherlands B.V.* to transform its IT landscape and enhance customer experience across their enterprise and consumer segments. By combining AI and deep consulting expertise, Wipro will help Odido improve customer engagement and satisfaction, improve productivity, and streamline operations to reduce costs. A key highlight of this multi-year engagement is the use of a self-funded model, where productivity-driven savings are reinvested to continuously fund new digital initiatives, ensuring that innovation remains both sustainable and scalable. As part of the engagement, Wipro will lead a full-scale modernization of Odido’s digital and enterpri
Klarna Set to Take off With Lufthansa Group, Bringing Flexible Payments to Travellers Across Europe and the U.S.27.11.2025 14:00:00 CET | Press release
Klarna, the global digital bank and flexible payments provider, today announces a new multi-market partnership with Lufthansa Group, Europe’s leading airline group. The new agreement is facilitated by Klarna’s integration with Adyen, the financial technology platform of choice for leading businesses. From November, Lufthansa Group customers will be able to choose Klarna’s flexible payment options at checkout when booking travel experiences. This new integration gives travellers greater control and convenience by offering the choice to pay in full, pay later, or spread the cost of their journey over time. The new options will be available first to customers in Austria, Belgium, Denmark, Finland, Germany, the Netherlands, Norway, Sweden, Switzerland, and the United States. “Travel is one of the most meaningful investments people make,” said David Sykes, Chief Commercial Officer at Klarna. “Together, we’re giving travellers the confidence to book their trips their way—with more flexibilit
GE HealthCare announces CE Mark for new digital 4D SPECT/CT system, StarGuide GX27.11.2025 12:06:00 CET | Press release
FOR USE IN CE-MARK EUROPEAN COUNTRIES ONLY StarGuide GXi empowers personalized care and research innovation as nuclear medicine expands into new applications The system doubles volume sensitivity,ii maintains high resolution and enables clinicians to virtually scan all energies fast – including the acquisition of investigational alpha emitters like Actinium-225 – with exceptional clarity and quantitation GE HealthCare today announced CE Mark for its new StarGuide™ GX system,i a new digital 4D SPECT/CT designed with excellent precision, clinical efficiency and impressive versatility. This milestone marks a significant moment in molecular imaging’s evolution, helping empower clinicians to expand research and help personalize care across a growing range of nuclear medicine applications and tracers – including the acquisition of alpha emitters. StarGuide GX comes at a pivotal time for the field of nuclear medicine. As complex diseases such as cancer, Alzheimer’s and cardiovascular disease
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom